Preview

Epilepsia and paroxyzmal conditions

Advanced search

EXPERIENCE REPLACEMENT DRUGS OF VALPROIC ACID IN CHILDREN OUTPATIENT CLINIC

Full Text:

Abstract

Abstract: the article presents the clinical observation of outpatients with a diagnosis of epilepsy in the children’s neurological department Morozovsky Children Hospital translation from the original on generic drug valproic acid. Such changes in anticonvulsant therapy in patients quarter led to a deterioration of the disease in the form of clinical remission failure, impairment at lectroencephalography, as well as the emergence of side effects from the gastrointestinal tract and deterioration of cognitive functions. On the basis of this observation can be confirmed by the fact that patients with epilepsyin remission is not recommended translated from the original drug to a generic.

About the Authors

I. O. Schederkina
Morozov Children’s Clinical Hospital, Moscow
Russian Federation


N. N. Zavadenko
Pirogov Russian National Research Medical University, Moscow
Russian Federation


I. E. Koltunov
Morozov Children’s Clinical Hospital, Moscow
Russian Federation


References

1. Верткин А.Л., Талибов О.Б. Генерики и эквивалентность – что стоит за терминами. Неотложная терапия. 2004; 1-2: 16-17.

2. Власов П.Н., Шафова Н.В. Эффективность и переносимость терапии эпилепсии при вынужденной замене противоэпилептических препаратов. Лечащий врач. 2007; 8: 75-77.

3. Карлов В.А. Стратегия и тактика лечения эпилепсии сегодня. Журнал неврология и психиатрия. 2004; 8: 28-34.

4. Соколов Ю.Б. Сравнительная фармакокинетика препаратов вальпроевой кислоты с контролируемым высвобождением. Ремедиум. 2006; 4: 2-7.

5. Тарловская Е.И. Генерики и оригинальные препараты: взгляд практического врача. РМЖ. 2008; 16 (5): 333-336.

6. Besag F.M.C. Is generic prescribing acceptabl in epilepsy? Drug safety. 2000; 23 (23): 173-182.

7. Bialer M., Yacobi A., Moros D. et al. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia. 1998; 39: 513-519.

8. Argumosa A., Herranz J.L. The clinical and economic impact of generic drugs in the treatment of epilepsy. Rev. Neurol. 2005; 41: 45-9.

9. Crawford P., Feely M., Guberman A., Kramer G. Are there potential problems with generic substitution of antiepileptic drugs: a review of issues. Seizure. 2006; 15: 165-76.

10. Perucca E., Gram L., Avanzini G., Dulac Q. Antiepileptic drugs as a cause of worsering seizures. Epilepsia. 1998; 39: 5-17.

11. Simeons S., De Coster S. Sustaining generic medicines markets in Europe. – Leuven: Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universitiet Leuven, 2006.

12. Vadney V.J., Kraushaar K.W. Effects of switchin from Depakene to generic valproic acid on individuals with mental retardation. Ment. Retard. 1997; 35: 468-472.

13. Wilner A.N. Therapeutic equivalency of generic antiepileptic drugs: results of a survey. Epilepsy &Bahavior. 2004; www.scien-cedirect.com.


For citation:


Schederkina I.O., Zavadenko N.N., Koltunov I.E. EXPERIENCE REPLACEMENT DRUGS OF VALPROIC ACID IN CHILDREN OUTPATIENT CLINIC. Epilepsia and paroxyzmal conditions. 2013;5(4):49-53. (In Russ.)

Views: 101


ISSN 2077-8333 (Print)
ISSN 2311-4088 (Online)